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1. Introduction 
The use of radioisotopes is important in pharmaceutical research and development (R&D). 
They are frequently used in non-clinical and clinical studies for the development of 
compounds for different therapeutic areas, such as central nervous system (CNS) diseases 
(e.g. Dementia, Alzheimer’s disease (AD), and Parkinson’s disease), oncology, and 
metabolic diseases (e.g. diabetes mellitus). 
Pharmaceutical companies invest a lot of time and money in research on new treatment 
strategies for diseases with a high medical need, such as oncology and metabolic diseases. A 
large amount of drugs fails during development due to toxicity and/or the lack of efficacy 
(Kola, I, 2008). Several attempts are being made to improve this, such as obtaining a better 
understanding of the pathophysiology of diseases, development of robust animal models, 
the application of biomarkers, development of pharmacokinetic (PK) - pharmacodynamic 
(PD) models, and the application of non-invasive techniques such as positron emission 
tomography (PET) in an early stage of development.  
2. Application of radiolabeled compounds 
A variety of radioisotopes is used in the R&D of drugs, such as 3H, 14C, 32P, 35S and 131I 
(Penner et al, 2009). Carbon-14 is the isotope of choice in most of the ADME studies. The 
labeled part of the drug molecule should not be lost in metabolite formation. Tritium-
labeled drugs are also used commonly, but have the risk of tritium exchange. Data from 
non-clinical studies performed with radiolabeled drugs can provide information to make the 
choice of the radioisotope and its position in the drug molecule. The tritium- or carbon-14-
labeled drug at the metabolically stable position should have a radiochemical purity of 
98%, and in special cases 95% may be acceptable. stability of the radiolabeled drug under 
dosing conditions should be checked at predose and postdose. 
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The advantage of using radiolabeled drugs is that the radioactivity can easily be detected 
and quantified using liquid scintillation techniques and disposition of drugs can be 
assessed. The choice of the radioisotope, the position of the radiolabel in the drug 
compound, radiochemical purity, and the specific activity are important parameters. These 
parameters can have an effect on the metabolic, chemical, and radiochemical stability of the 
drug, metabolite formation and detection, and the recovery of radioactivity.  
2.1 Non-clinical studies 
Radioactive labeled compounds are used in non-clinical studies to assess drug absorption, 
distribution, metabolism, and excretion (ADME). They can provide information on a) drug 
absorption in cell lines, b) P-glycoprotein (P-gp) transport or inhibition, c) metabolite profiling, 
d) drug transport (uptake, efflux), and e) drug binding to receptors (Marathe et al., 2004).  
Other applications of radiolabeled compounds are to investigate apoptosis (Glaser et al., 2003), 
DNA replication and cell cycle progression (Hoy et al., 1990) in oncology. In the development 
of gemcitabine, a pyrimidine nucleoside anticancer drug, radiotracers were used to better 
understand the pharmacology and toxicology of this compound (Heinemann et al., 1988; 
Mackey et al., 1988). With the use of radiolabeled [3H]-gemcitabine, its synthesized metabolite 
[3H]-dFdU, and [3H]-thymidine, novel active metabolites of gemcitabine were revealed, which 
turned out to be incorporated into DNA, formed in vivo in mice and accumulated into the liver 
following multiple oral dosing (Veltkamp et al.,2008a, 2008b). These findings gave new 
insights in the metabolism, pharmacology and toxicology of the drug. 
2.2 Clinical studies 
Administration of radiolabeled compounds to humans is not generally done in the first-in-
man study. Considering the amount and type of information that human ADME studies can 
provide, it should be considered to conduct these studies early during clinical development. 
Possibilities are just after or in parallel with the multiple ascending dose (MAD) study. 
Radiolabeled drugs are used in a variety of clinical studies, such as in mass balance (MB), 
regional drug absorption, and microdose studies.  
Mass balance studies provide valuable information on the absorption, metabolism, and 
elimination of a drug. Identification and quantification of metabolites is important in MB 
studies (Penner et al., 2009).  
Regional drug absorption studies can be performed to determine the PK of a drug from a new 
modified release (MR) compared to a more conventional immediate release (IR) formulation 
and to measure absorption from specific areas of the gastrointestinal (GI) tract, such as the 
distal small bowel, ascending colon, and transverse colon. In this way, it can be determined 
whether the drug is sufficiently absorbed from the GI tract and together with other PK and its 
safety it can be determined whether development of a MR formulation would be beneficial.  
Microdose studies can give important information on the distribution and metabolism of a 
new drug. It can also help to reduce the number of animals used in non-clinical studies 
(Combesa et al., 2003). There has been a growing interest in the safety of drug metabolites, 
particularly those not produced in experimental animals. In order to avoid unpredictable 
toxicity caused by such metabolites, the US Food and Drug Administration (FDA) issued the 
Guidance for Safety Testing of Drug Metabolites (MIST) in 2008 (FDA, 2008). It recommends 
that, before commencing phase III trials of a drug, a safety report must be prepared relating 
to drug metabolites that have a systemic exposure >10% of the parent drug and those that 
occur in significantly greater quantities in humans than in experimental animals.  
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Subsequently, the International Conference on Harmonisation, ICHM3 guidance, 
recommends safety assessment of metabolites whose exposure is >10% of the total exposure, 
not of the parent compound (ICHM3, 2009). This new guideline prompted the 
pharmaceutical industry to identify and quantify drug metabolites in humans in the early 
phases of drug development. 
In microdose studies PK data are obtained after administration of a trace subpharmacologic 
quantity to human subjects (Lappin et al., 2006). The ultrasensitive analytic technique of 
accelerator mass spectrometry (AMS) has been used to quantify the low plasma 
concentrations anticipated after microdose administration. These studies do not provide 
information about the safety and tolerability of the drug. Requirements for microdose 
studies have been summarized by the EMEA, FDA and others (EMEA, 2003; FDA, 2006; 
Bergstrom et al., 2003; Marchetti et al., 2007). 
3. PET imaging 
3.1 Principles of PET 
PET is a nuclear imaging technique used to map biological and physiological processes in 
living subjects following the administration of positron emitting radiopharmaceuticals. The 
technique is based on the detection of photons released by annihilation of positrons emitted 
by radioisotopes. Positron-emitting radionuclides are produced in a cyclotron by 
bombarding target material with accelerated protons. In the body, these radionuclides emit 
positrons that undergo annihilation with nearby electrons, resulting in the release of two 
photons. These so-called annihilation photons are detected by imaging and the resulting 
data can be used to reveal the distribution of the radiotracer in the body. 
Unlike conventional imaging modalities, such as magnetic resonance imaging (MRI) or 
computed tomography (CT), which mainly provide detailed anatomical images, PET can 
measure biochemical and physiological aberrations that occur prior to macroscopic 
anatomical signs of a disease, such as cancer (Chen et al., 2011). Currently, many positron 
emitting isotopes are available with different characteristics (see Table 1). Fluorine-18 has 
the advantage of having a long half-life (t1/2), which enables time-consuming radiosyntheses 
and imaging procedures. 
 
Isotope t1/2 
18F 109.8 min 
11C 20.4 min 
15O 2.04 min 
13N 9.97 min 
64Cu 12.7 hours 
68Ga 68.1 min 
124I 4.2 days 
Table 1. Positron emitters commonly used in PET studies. 
3.2 Application of PET imaging 
PET imaging has become an important tool in the process of drug development for a variety 
of compounds, such as for CNS targeted and anticancer drugs. PET imaging has the 
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advantage of having high sensitivity and high specificity when using the appropriate PET 
probes. Therefore, it can be used for examination of the physiology of tissues and for 
evaluation of the distribution of a drug in specific organs or regions in a quantitive manner. 
PET imaging is used to examine the PK of drugs in tissues using a positron-labeled drug 
candidate or the PD (e.g. target expression, occupancy) using the radiolabeled drug itself or 
a different target-specific tracer. PET radiotracers used in R&D of drugs in the field of CNS, 
oncology and diabetes mellitus are listed in Table 2.  
 
a. CNS 
 
PET tracer Target Purpose 
[11C]-PIB 
(Rostomian et al., 2011) 
Amyloid plaque Diagnosis of Alzheimer’s 
disease and efficacy on A 
plaques 
[18F]-AV45 
(Wong et al., 2010) 
Amyloid plaque Diagnosis of Alzheimer’s 
disease and efficacy 
measurement of A plaques 
[18F]-FK960 
(Noda et al., 2003a) 
Hippocampus (exact target 
not identified yet) 
Dose setting  
Dementia 
[11C]-SCH442416 
(Mihara et al., 2008) 
Adenosine A2AR* Determine receptor binding 
of a therapeutic drug 
Parkinson’s disease 
[18F]-FDG 
(Asai et al., 2009) 
Glucose metabolism 
(rCMRglu**) 
Diagnosis of Alzheimer’s 
disease 
*Adenosine A2AR, adenosine A2A receptor; **rCMRglu, regional cerebral metabolic rate of glucose. 
 
b. Oncology 
 
PET tracer Target Purpose 
[18F]-FDG Glucose metabolism Tumor response/disease 
staging 
[18F]-FLT Cell proliferation Tumor response  
[11C]-Gly-Sar 
(Mitsuoka et al., 2008) 
Peptide transport Cancer detection 
(distinction between cancer 
and inflammatory tissue) 
[11C]-methionine 
(Narayanan et al., 2002) 
Amino acid metabolism Tumor response (brain 
tumors) 
[18F]-FMISO 
(Bruehlmeier et al., 2004) 
Hypoxia Diagnosis of hypoxic state 
of cancer 
[18F]-FAZA 
(Piert et al., 2005) 
Hypoxia Diagnosis of hypoxic state 
of cancer 
FDG; fluorodeoxyglucose; FLT; fluorothymidine; Gly-Sar, glycylsarcosine; FMT, fluoromethyltyrosine; 
FMISO, fluoromisonidazole; FAZA, fluoroazomycin-arabinofuranoside. 
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c. Diabetes mellitus (see also sections 3.3.3 and 3.4.3) 
 
PET tracer Target  Purpose 
[11C]-DTBZ VMAT2 -cells pancreas Assessment of -cell mass 
[18F]-FP-(+)-DTBZ (AV133) VMAT2 -cells pancreas Assessment of -cell mass 
[18F]-FP-(+)-epoxy-DTBZ VMAT2 -cells pancreas Assessment of -cell mass 
DTBZ, dihydrotetrabenazine; VMAT2, vesicular monoamine transporter 2; FP-DTBZ, fluoropropyl-
dihydrotetrabenazine.  
Table 2. PET radiotracers in R&D of drugs in the field of CNS (a), oncology (b) and diabetes 
mellitus (c). 
Amyloid plaque is a major feature of Alzheimer’s disease (AD), for which several amyloid-
imaging tracers have been developed (Kadir et al., 2010). Among these tracers, [11C]-PIB and 
[18F]-AV45 were examined as diagnostic agents for in vivo imaging of amyloid deposition in 
humans. According to the National Institute on Aging and Alzheimer's Association Lead 
Effort to Update Diagnostic Criteria for Alzheimer's Disease, biomarkers for AD have been 
developed and are being validated. These fall into several categories and include biomarkers 
for a) beta amyloid pathology, including amyloid PET imaging and levels of beta amyloid in 
cerebrospinal fluid (CSF), b) neuronal injury, including levels of CSF τ and phospho-τ, c) 
neuronal dysfunction, including decreased uptake of FDG on PET scans, and d) 
neurodegeneration, including brain atrophy on structural MRI scans. 
PET imaging in oncology is used to assess tracer distribution and extent of uptake to 
identify the disease, for disease staging, and for monitoring therapeutic response. The most 
widely used PET tracer in oncology is [18F]-fluorodeoxyglucose ([18F]-FDG), a glucose 
analog that enters the cell after uptake by glucose transporter 1 (GLUT1). FDG is 
subsequently phosphorylated by hexokinase-II and accumulates in tumor cells, a 
mechanism also called metabolic trapping. In fact, increased glucose transport is associated 
with elevated glycolysis of the cancer cell and a corresponding increase in hexokinase 
activity. Tissues that metabolize gucose faster will accumulate more [18F]-FDG. Therefore, 
cancer cells can be differentiated from benign tissues by their increased metabolism. 
Correspondingly, this uptake can be semi-quantified on PET.  
However, [18F]-FDG is not a target-specific tracer and it cannot differentiate between cells 
that have a high metabolic rate associated with neoplasia, and those for which the increased 
metabolic rate is associated with other etiologies, such as infection or inflammation. In 
addition, many malignancies do not exhibit high metabolic rates and, thus, are not properly 
diagnosed by [18F]-FDG (Chen et al., 2011).  
A novel PET tracer, [11C]-glycylsarcosine ([11C]-Gly-Sar), targeted to H+/peptide 
transporters (PEPTs) was investigated for its specificity as compared to that of FDG in 
distinguishing between tumor and inflammatory tissues (Mitsuoka et al., 2008; Fig. 1). After 
i.v. administration of [11C]-Gly-Sar to mice, it was possible to visualize prostate, pancreatic 
and gastric tumor xenografts all expressing PEPTs. Accumulation of [11C]-Gly-Sar occured 
in kidneys and bladder, and was low in other tissues (e.g. brain, heart, lung, and liver), 
which had restricted functional expression of PEPTs. Accumulation of [18F]-FDG occured in 
brain, heart, kidneys and bladder. The detection of tumors in mice was improved using 
[11C]-Gly-Sar compared to [18F]-FDG (Fig. 1). Whereas 18F-FDG accumulated also in 
inflammatory tissue, uptake of [11C]-Gly-Sar was absent in inflammatory tissues. [11C]-Gly-
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Sar is a promising tumor-imaging agent and appears superior to FDG for distinguishing 
between tumor and inflammatory tissue.  
 
 
 
Fig. 1. Planer images of mice bearing human pancreatic tumors after injection of AsPC-1 
pancreatic adenocarcinoma cells in their right hind limb. [11C]-Gly-Sar (~ 5 MBq) or [18F]-
FDG (~ 5 MBq) were administered i.v. Turpentine oil was administered subcutaneously into 
the left hind limb of control mice (left mice for [11C]-Gly-Sar and [18F]-FDG) to induce 
inflammation. Yellow arrowhead, tumor; red arrowhead, inflammation.  
Another promising radiopharmaceutical is 3'-deoxy-3'-[18F]-fluoro-L-thymidine (FLT), a 
marker for cell proliferation. Accumulation of FLT in tumor cells has been shown to be 
dependent on the activity of cellular thymidine kinase-1 (TK1). TK1 is the key enzyme and 
limiting step in the pyrimidine salvage pathway of DNA synthesis and is overexpressed in 
most tumor types. Intracellarly, FLT is phosporylated to FLT-monophosphate, but unlike 
thymidine, FLT is not incorporated into DNA as it lacks the 3’-hydroxyl group. As TK1 is 
functional only in the late G1- and S-phase of the cell cycle, FLT uptake closely correlates 
with the amount of proliferating cells. L-[methyl-11C]-methionine, or [11C]-methionine, is a 
PET tracer for amino acid metabolism used in neuro-oncology, which makes it possible to 
assess the characteristics of lesions in the brain, impossible with FDG-PET or MRI. The 
uptake of [11C]-methionine provides information on the malignancy of lesions. Sodium-
independent amino acid transporters (LATs), which mediate transport of large branched 
and aromatic amino acids, has attracted special interest, because system L is commonly 
upregulated in many tumors and correlates with tumor growth and prognosis. Other amino 
acid tracers have been developed to detect cancers. On the other hand, the prevalence of 
hypoxic areas is a characteristic feature of locally advanced solid tumours and has been 
described in a wide range of human malignancies. Evidence from experimental and clinical 
studies point to a role for tumor hypoxia in tumor propagation, resistance to therapy and 
malignant progression. To monitor the hypoxia, nitroimidazole compounds such as [18F]-
fluoromisonidazole (FMISO)or [18F]-fluoroazomycin-arabinofuranoside (FAZA) have been 
described. These compounds are degraded into reactive intermediate metabolites by 
intracellular reductases in a process which is directly related to the level of 
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oxygenation/hypoxia. This causes a gradient which is favorable for detection of hypoxic 
cells. Subsequently, these metabolites covalently bind to thiol groups of intracellular 
proteins and thereby accumulate within viable hypoxic cells. 
PET images from orthotopically implanted pulmonary human tumor xenografts in mice are 
shown in Figure 2. The micro-PET images were coupled to micro-CT images in the lung. By 
using different radiotracers, these PET images provided information on the tumor 
condition, such as on glucose metabolism ([18F]-FDG), cell proliferation ([18F]-FLT], and 
hypoxia [18F]-FMISO]. Micro-PET/CT imaging could be a robust surrogate biomarker for 
antitumor activity in preclinical studies.  
Assessment of treatment response is essential for disease management. Anatomic imaging 
alone using the Response Evaluation Criteria in Solid Tumors (RECIST) does not reflect 
physiological changes of the tumors, and therefore still has limitations in response 
evaluation. Functional imaging is very useful in the evaluation of the efficacy of novel 
anticancer drugs. 
 
 
Fig. 2. PET, CT, and combined PET/CT-images of orthotopic human lung tumor xenografts 
in mice. Mice were administrated via the tail vein 15 MBq of [18F]-FDG for detection of 
glucose metabolism (top row), [18F]-FLT for detection of cell proliferation (middle row) and 
[18F]-FMISO for detection of hypoxia (bottom row). PET images were acquired for 50 to 60 
min after tracer administration using three-dimensional ordered subset expectation 
maximization (3D-OSEM) reconstruction. 
3.3 Examples of PET in non-clinical studies 
Several examples of the application of PET in non-clinical studies for the development of 
CNS drugs, anticancer drugs and antidiabetic drugs is described in this Section.  
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3.3.1 Determination of the PK and PD of CNS drugs 
The brain anatomy and function can be visualized using PET scanning in conjunction with a 
very small amount of a radiolabeled compound. It is also a useful technique to assess the PK 
of radioactive labeled therapeutic agents, and is commonly used in the development of CNS 
targeted drugs to determine the extent of brain penetration of the drug. After administration 
of the radioactive labeled therapeutic drug, the drug exposure in different areas of the brain 
can easily be determined noninvasively by measurement of the radioactivity with PET. In 
preclinical PET studies, the radioactive labeled drug is often evaluated in well-trained 
rhesus macaques in conscious condition without anxiety and stress. PET results in conscious 
monkeys are considered preferable above sedated monkeys for predicting brain penetration 
of a CNS drug in human, since anesthesia does depress the neuronal activity, regional 
cerebral blood flow (rCBF), and regional cerebral metabolic rate for glucose (rCMRGlu) in 
animal experiments.  
For successful drug development, optimal dose setting in clinical trials is important. Because 
each drug has its corresponding target site, achievement of the most suitable drug 
concentration in the target organ or tissue becomes critical to allow the drug to exhibit its 
maximal effect. Although PK data in animal experiments are usually used to estimate the 
clinical dose, discrepancies in absorption, distribution, and metabolism of drugs between 
experimental animals and humans still remains in most cases, and these make the dose 
estimation difficult. Especially when a drug acts in the brain, further difficulty is caused by 
the presence of the blood-brain barrier. 
FK960, (N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate) is a novel drug in 
development for Dementia. Its proposed mechanism of action is enhancement of 
somatostatin release in the hippocampus. Since somatostatin also enhances the release of 
acetylcholine, FK960, could indirectly activate the release of acetylcholine. FK960 improved 
memory impairment in several kinds of rodent and non human primate animal models. 
However, the dose-response relationships of FK960 in memory improvement in animal 
models of amnesia and in the enhancement of long-term potentiation (LTP) in hippocampal 
slices were bell shaped. Therefore, the optimal dose setting to exhibit efficacy in patients 
remains to be exactly determined. Because PET can measure radioactivity concentrations 
dynamically in a target organ in a living subject with minimal invasion, the acquisition of 
bridging data between animals and humans may be expected. 
[18F]-FK960 was synthesized and administered orally in combination with non radioactive 
labeled drug to conscious rhesus monkeys. Drug concentration versus time profiles in 
plasma and the brain were obtained using PET imaging (Noda et al., 2003a; Fig. 3). Dynamic 
PET images were acquired for 4 hours from 5 min after drug administration. Arterial blood 
samples were drawn during the PET scan and analyzed by an auto well Ǆ-counter and thin 
layer chromatography to determine [18F]-FK960 activity in plasma. FK960 concentrations 
(mol/L) were calculated using the specific activity of FK960. 
The study demonstrated that [18F]-FK960 penetrated the blood-brain barrier and distributed 
dose-dependently into the entire brain. Maximal FK960 brain concentrations were 
comparable with the levels showing enhancement of LTP in hippocampal slices. The results 
suggested that this PET imaging method could be used to measure FK960 brain 
concentrations in humans. A different study showed that FK960 significantly improved 
regional cerebral blood flow and regional cerebral metabolic rate of glucose in conscious 
aged macaques (Noda et al., 2003b). 
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(A)          (B) 
  
Fig. 3. (A) Brain and plasma concentrations of FK960 versus time in conscious male 
monkeys (n=3) after oral administration of a mixture of 0.1 mg/kg of FK960 and 370 MBq 
tracer of [18F]-]FK960 in saline. Concentrations of the drug into the entire brain were 
obtained from PET data. (B) Transverse PET images showing distribution of [18F]-FK960 into 
the brain. PET images were taken 90-120 min after drug administration as 3.6 mm transverse 
slices from the lower brain (top left) to the upper brain (bottom right). FK960 reached higher 
concentrations in the lower brain compared to the upper brain. The circle as presented in 
image 12 indicates the brain area in the skull. 
Besides determination of the PK of a drug, PET imaging is important to assess the PD of 
drugs and is used in receptor and transporter occupancy studies, e.g. to investigate binding 
of the PET tracer to the target (receptor/transporter) and inhibition of this PET tracer 
binding by the drug of interest. These occupancy studies can reveal information on the 
binding potency and durability of binding in vivo, which can be used for dose selection.  
In this way, PET imaging can be used to determine both the PK and PD of a drug and to 
establish the relationships between plasma and brain levels with the extent of receptor 
occupancy by the drug.  
The use of PET to determine PD drug effects were gently shown for ASP5854 (5-[5-amino-3-
(4fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one), a novel adenosine A2A 
receptor (A2AR) antagonist, in development for Parkinson’s disease. Adenosine A2ARs are 
abundantly expressed in the striatum of several species. They are co-expressed with 
dopamine D2 receptors in the GABAergic striatopallidal neurons. Stimulation of adenosine 
A2ARs decreases the binding affinity of D2 receptors and elicits effects opposite to the ones 
shown by D2 receptor activation. These observations suggested that antagonistic adenosine-
dopamine interactions can be important in the regulation of the activity of the basal ganglia 
and could explain the stimulating effects of adenosine A2AR antagonists on motor behavior. 
Therefore, ASP5854 was considered of potential interest in the treatment of movement 
disorders and may reduce the symptoms in Parkinson’s disease.  
ASP5854 and [11C]-SCH442416, an adenosine A2AR-specific radiotracer, were administered 
i.v. to conscious rhesus monkeys and adenosine A2AR occupancy in the brain was examined 
using PET. ASP5854 dose-dependently increased adenosine A2AR occupancy in the striatum 
(Mihara et al., 2008; Fig. 4) and showed long-lasting occupancy even at decreasing drug 
concentrations in plasma. 
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(A)        (B) 
  
Fig. 4. (A) PET images of [11C]-SCH442416 before and after treatment of adenosine A2A 
receptor antagonist, ASP5854, in conscious monkeys. At baseline, the tracer accumulated in 
the striatum, which is rich of A2A receptors (20 mCi, i.v. injection; mean of six animals). At 
t=1h after drug administration (0.1 mg/kg, i.v.), the accumulation of the tracer in the 
striatum was lower compared to baseline, due to decreased binding of the PET tracer to the 
receptor as a result of ASP5854 binding to the receptor. (B) Relationship between the dose 
and receptor occupancy at 1 h after drug administration. Sigmoidal dose-response curve 
demonstrating an increase in adenosine A2AR occupancy by ASP5854 with an increase in 
ASP5854 plasma concentration at t=1 h after drug administration (dose-levels: 0.001 to 0.1 
mg/kg, i.v.); 80% receptor occupancy correlated with efficacy (catalepsy) in the monkeys.  
Donepezil, an acetylcholine esterase inhibitor (AChEI), has been recommended as a 
treatment option for patients with AD. [18F]-fluoro-2-deoxyglucose (FDG)-PET was used to 
measure the regional cerebral metabolic rate of glucose (rCMRglu), an index of neuronal 
activity, in rhesus monkeys (Asai et al., 2009). The effects on rCMRglu were measured 
following intramuscular (i.m.) administration of donepezil (500 g/kg) or the non-selective 
muscarinic ACh receptor antagonist scopolamine (30 g/kg, i.m.), or co-administration of 
both drugs. This FDG-PET study showed that administration of donepezil or scopolamine 
alone increased rCMRglu in conscious rhesus monkeys. The donepezil-induced increase in 
rCMRglu was abolished by simultaneous administration of scopolamine, suggesting that 
muscarinic ACh receptor function plays an important role in the effect of donepezil (Fig. 5).  
3.3.2 Determination of early tumor response to anticancer drugs 
Oncology is a main therapeutic area of many pharmaceutical companies. PET imaging is 
helpful to measure early tumor response to anticancer treatment in early phases of research 
and development.  
YM155 is a small molecule survivin suppressant. Survivin is a member of the inhibitor of 
apoptosis protein family, acting as an inhibitor of caspase activation, and has been 
implicated in both cell survival and regulation of mitosis in cancer. Although survivin is 
expressed in a variety of normal fetal tissues, expression is absent in most adult tissues. In 
contrast, survivin is highly expressed in most tumors. Survivin overexpression in cancer 
patients is associated with resistance to cytotoxics and is correlated with poor survival. 
YM155 was shown to have nanomolar antitumor activity in a wide variety of human cancer 
cell lines. The continuous infusion of YM155 induced tumor regression in mice xenograft 
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Fig. 5. PET images of the brain of consious monkeys demonstrating rCMRglu using FDG-
PET after treatment with empty vehicle (a), donepezil 500  μg/kg (b), scopolamine 30 μg/kg 
(c), and donepezil+scopolamine (d). Images are orbitomeatal transverse slices (OM) + 0 to 
OM + 32.4 mm, 3.6 mm thick. 
models (Nakahara et al., 2011a). Other results suggested that YM155 sensitized tumor cells 
to radiation (Iwasa et al., 2008) and platinum compounds both in vitro and in vivo, and that 
the effect was likely attributable to the inhibition of DNA repair and consequent 
enhancement of apoptosis (Iwasa et al., 2010). Non-clinical studies using radioactive 14C-
labeled YM155 demonstrated that the organic cation transporter 1 (OCT1) was the 
predominant transporter for the hepatic uptake of YM155 (Iwai et al., 2009). YM155, 
administered as 168 hours continuous infusion in 21-day cycles, appeared to be safe and 
well-tolerated, with a maximum tolerated dose of 8.0 mg/m2/day in Phase I studies in 
patients with advanced refractory solid tumors (Satoh et al., 2009), and advanced solid 
tumors or lymphoma (Tolcher et al., 2008). Multi-center Phase II trials demonstrated the 
safety and tolerability of YM155 in patients with unresectable stage III or IV melanoma 
(Lewis et al., 2011) and safety and modest activity in patients with advanced refractory non-
small cell lung cancer (NSCLC) (Giaccone et al., 2009).  
PET imaging has been used for the development of YM155 in preclinical studies in mice. 
[18F]-FDG-PET has been used to assess early treatment response in animals with diffuse 
large B-cell lymphoma (DLBCL) and non-small cell lung cancer (NSCLC) xenografts, and 
[18F]-FLT-PET was used to determine the effect on cell proliferation. The combined effect of 
YM155 and docetaxel in human NSCLC xenografts was determined using whole-body 
imaging. Combination treatment of YM155 and docetaxel for 21 days resulted in increased 
inhibition of tumor growth (Nakahara et al., 2011b), accompanied by inhibition of tumor 
uptake of FDG, compared to monotherapy with either YM155 or docetaxel (Fig. 6).  
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Fig. 6. Whole-body imaging of mice with [18F]-FDG. Human NSCLC xenografts were grown 
after injection of Calu-6 human tumor cells (3×106 cells/100 µL) into the right hind limb of 
male Balb/c nude mice, aged 6-7 weeks. YM155 (2 mg/kg/day) was administred as s.c. 
infusion for 7 days. Docetaxel (10 mg/kg) was administered as i.v. bolus injection on days 0, 
4 and 8 after the initiation of YM155 treatment. Mice were administerd 5 MBq of [18F]-FDG 
i.v. via the tail vein. After the appropriate time had elapsed, mice were anesthetized by 
isoflurane, placed in a prone position, and imaged by using a planar positron imaging 
system PPIS-4800 (Hamamatsu Photonics) to obtain the whole-body distribution of [18F]-
FDG at 50–60 min from tracer injection.  
3.3.3 Measurement of pancreatic -cell mass in the development of antidiabetic drugs 
Pancreatic ǃ-cell mass (BCM) is known to decrease as a result of progression of disease in 
animals with diabetes mellitus. Measurement of BCM in vivo is an important tool for early 
diagnosis of diabetes mellitus and to monitor the efficacy of the treatment. Historically, the 
pancreas has been a difficult organ to image because of its retroperitoneal location and 
overlying visceral organs. Over the past 2 decades, the advance of CT and MRI has allowed 
to correlate disease processes of the pancreas, such as pancreatitis with anatomical 
structures. Unfortunately, these imaging modalities do not describe organ function or easily 
separate the endocrine from the exocrine pancreas. The ability to quantify and monitor -
cell mass (BCM) is of particular interest for diabetes mellitus.  
Recently, it was reported that vesicular monoamine transporter 2 (VMAT2) is expressed 
mainly on the pancreatic ǃ-cells as well as on dopaminergic neurons. A VMAT2 ligand, 
dihydrotetrabenazine (DTBZ), was developed previously for dopaminergic neuron imaging 
in the striatum and it has been successfully applied for PET studies of Parkinson’s disease. 
DTBZ can also be used to monitor BCM quantitatively for diabetes. PET tracers that have 
been used to quantify VMAT2 are [11C]-dihydrotetrabenazine ([11C]-DTBZ) (Souza et al., 
2006(a); Simpson et al., 2006; Murthy et al., 2008; Goland et al., 2009), [18F]-fluoropropyl-
DTBZ ([18F]-FP-DTBZ or [18F]-AV-133) (Kung et al., 2007; Kung et al., 2008(a); Tsao et al., 
2010) and [18F]-fluoropropyl-DTBZ epoxide ([18F]-FP-epoxy-DTBZ) (Kung et al., 2008(b)), 
which were shown to have high potency and selectivity for binding to VMAT2 in rats. 
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Longitudinal preclinical studies have been performed in induced T1DM and obese rat 
models (Freeby et al., 2008) and in a spontaneous T2DM diabetic rat model showing a 
decrease in [11C]-DTBZ uptake that anticipated loss of glycemic control (Souza et al., 
2006(a)). These preclinical in vivo PET studies in non-human primates are used to evaluate 
the between-species differences in PK of the tracer, and to establish the most likely optimal 
tracer for PET studies to establish BCM in humans. 
3.4 Examples of PET in clinical studies 
Several examples of the application of PET in clinical studies for the development of CNS 
drugs, anticancer drugs and antidiabetic drugs is described in this Section.  
3.4.1 Biodistribution of CNS drugs in humans 
Establishing the therapeutic dose and dose regimen of a new drug is challenging, especially 
for drugs with CNS activity. The major challenge is the blood-brain barrier (BBB), which 
limits the access of drugs to the brain tissue. It is important to select the right dose range of a 
drug in early phase clinical trials to establish the PK, PD and safety of a drug. PET is used to 
determine biodistribution and concentration of a drug in the brain non-invasively, in vivo. In 
such clinical investigation, Good Manufacturing Practice (GMP) and Good Clinical Practice 
(GCP) regulations are required. As described earlier in this Chapter, PET was used in non-
clinical studies to predict the optimal clinical dose for FK960, a novel drug in development 
for the treatment of patients with Dementia. Subsequently, the drug was investigated in 
humans. FK960 has a bell-shaped dose–response relationship. Determining the proper 
clinical starting dose and dose range is difficult because of species differences between 
animals and humans. For example, differences in brain concentrations of the drug at 
comparable doses may be expected as a result of discrepancies in absorption, distribution, 
metabolism, and permeability of the drug through the BBB between animals and humans. 
This may lead to incorrect estimations of the therapeutic dose in humans from the animal 
data. Therefore it could be useful to determine drug concentrations in the brain, in addition 
to plasma, by PET in clinical studies.   
In a clinical study in healthy male subjects, concentration versus time profiles of FK-960 in 
plasma and different sections of the brain were determined following oral administration of 
FK-960 (Fig. 7). A mixture of [18F]-FK960 and FK960 (6 mg/man, male, n=3, p.o.) was 
administrated to healthy subjects. In addition, whole-body PET imaging was carried out 
between 120 and 130 min after injection, showing that [18F]-FK960 distributed to liver and 
kidneys, but not to the stomach and small intestine. The whole body scan suggested hepatic 
and renal clearance of FK960.  
3.4.2 PET imaging in clinical oncology 
In clinical oncology PET is used in the diagnosis of cancer, detection of metastasis and 
disease staging. It is also under investigation for the prediction of patient response to 
treatment (West et al., 2004). Early evaluation of treatment response can be of value to avoid 
unnecessary toxicity or ineffective treatment and to terminate development of uneffective 
drugs at an early stage, thereby saving costs of expensive late phase clinical studies. 
Currently, only two PET tracers have been described in a guidance by the FDA to assist 
applicants in preparing New Drug Applications (NDAs) (Guidance PET Drug 
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(A)                 (B) 
  
Fig. 7. (A) Concentration versus time curves of FK-960 in plasma and different area’s of the 
brain in healthy subjects following oral administration of a mixture of [18F]-FK960 and 
FK960 (6mg, n=3). (B) Biodistribution of [18F]-FK960 in human whole-body using PET 
imaging. Images were acquired 120-130 min after administration.  
Applications - Content and Format for NDAs and ANDAs, February 2011). There has been 
evidence that nuclear medicine imaging techniques could provide unique, biologically 
relevant, and prognostically important information unavailable through anatomic imaging 
such as CT or MRI. Multiple quantitative measurements can be performed by PET, which 
enables to monitor the effects of the treatment at an early stage, before those changes are 
detectable with conventional imaging modalities. The most important PET tracer in clinical 
oncology is FDG, which reflects glucose metabolism in the tumor. FDG-PET has shown to be 
of value in the differentiation of benign and malignant tissues, preoperative staging, 
detection of recurrent disease, and, more recently, in the identification of early tumor 
response to therapy. FLT-PET has attracted attention as a biomarker to evaluate tumor cell 
proliferation. The FDA has approved an investigational new drug (IND) application for 
[18F]-FLT, sponsored by the Society of Nuclear Medicine (SNM).  
Early response evaluation using FDG and FLT has been used for example for erlotinib 
(Tarceva), an inhibitor of the epidermal growth factor receptor (EGFR), used in the 
treatment of solid tumors, such as non-small cell lung cancer (NSCLC) and pancreatic 
cancer. [18F]-FDG PET has been recognized as an adequate staging tool in patients with 
NSCLC, and several studies suggested that the standardized uptake value (SUV) has a 
prognostic value in NSCLC. Furthermore, it has been reported that at an early stage during 
erlotinib therapy, [18F]-FDG PET/CT can predict treatment in NSCLC patients (Aukema et 
al., 2010).  
The accuracy of FDG-PET and FLT-PET were evaluated in patients with advanced NSCLC 
for early prediction of progression after 6 weeks of therapy wit erlotinib (Zander et al., 
2011). FDG-PET predicted progression-free survival (PFS), overall survival (OS), and 
absence of progression after 6 weeks of therapy with erlotinib in treatment-naive patients 
with advanced NSCLC independent from the EGFR mutational status. Moreover, it was 
reported that early FDG-PET response on day 14 after initiation of erlotinib therapy, was 
associated with improved PFS and OS, even in the absence of subsequent RECIST response 
(Mileshkin et al., 2011).  
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PET is also useful to assess the PK of the anticancer drug in tumor tissue. This is of 
particular interest for anticancer drugs, which have their target in the tumor cell, for 
example drugs that target mRNA of a specific cancer gene. Tumor cells generally 
overexpress efflux pumps, such as P-gp, which prevent anticancer drugs that are P-gp 
substrate, to enter the tumor cell, thereby causing tumor resistance to the treatment. This can 
lead to continuation of tumor cell proliferation, experience of unncessary adverse events of 
the chemotherapy, and delay in determination of the effective dose regimen or decision to 
switch to other potential effective treatment. The delivery of antisense oligonucleotide 
directed against survivin mRNA in tumor tissue was determined using [11C]-LY2181308 PET 
imaging in a phase 1 clinical study (Talbot et al., 2010).  
3.4.3 PET imaging to determine the effect of antidiabetic drugs on -cell mass 
It is considered important to evaluate the effect of glucose lowering drugs on preservation 
of pancreatic BCM in patients with T2DM, since BCM is affected by the disease. Overall 
pancreatic BCM reflects the balance between the dynamic processes of ǃ-cell expansion, 
through proliferation and neogenesis, and ǃ-cell loss via apoptosis. Given that BCM can be 
modified significantly by altering the rate of any of these mechanisms, therapies that 
modulate ǃ-cell expansion and loss have garnered recent interest. Therefore, it is also used 
as a tool to differentiate a novel antidiabetic drug in development from existing/marketed 
glucose lowering drugs with regard to its pharmacological activity.  In fact, pioglitazone 
treatment preserved pancreatic ǃ-cell morphology and ǃ-cell function in obese diabetic db/db 
mice (Kawasaki et al., 2005). Furthermore, pioglitazone protects human ǃ-cells against 
apoptosis or loss of function under exposure to interleukin-1ǃ or high-glucose 
concentrations in vitro (Zeender et al., 2004). In obese Zucker rats, rosiglitazone maintained 
ǃ-cell proliferation and prevented loss of ǃ-cells (Finegood et al., 2001). Recently, treatment 
with thiazolidinediones was reported to improve ǃ-cell function, which is strongly 
correlated with glycemic control, in patients with T2DM (Gastaldelli et al., 2007). DPP-IV 
inhibitors and incretins such as glucagon-like peptide-1 (GLP-1) and glucose-dependent 
insulinotropic polypeptide (GIP) stimulate not only insulin secretion but also augment BCM 
via ǃ-cell proliferation and neogenesis. Also, GLP-1 receptor signaling modifies the cellular 
susceptibility to apoptosis. Unfortunately, most studies measuring BCM have relied on 
postmortem examination of the pancreas, because until recently it was impossible to 
prospectively measure BCM in vivo. 
A PET study with [11C]-DTBZ quantified VMAT2 expression in the pancreas as a non-
invasive measurement of pancreatic BCM, and demonstrated differences in BCM between 
healthy subjects and patients with type 1 diabetes patients (T1DM) (Goland et al., 2009). 
Others demonstrated that [18F]-FP-DTBZ compared to [11C]-DTBZ substantially improved, 
both qualitatively and quantitatively, the ability to image pancreatic BCM in T1DM 
(Normandin et al, 2010). Futhermore, [18F]-FP-DTBZ was suggested to be safe and to be used 
for biodistribution and radiation dosimetry for imaging in humans and possibly to be used 
repetitively in longitudinal studies (Lin et al., 2010). Up to date, no PET studies for BCM 
determination have been published in T2DM patients. Others showed that since there is a 
significant BCM reserve, T2DM symptoms related to unstable glucose homeostasis are not 
obvious until BCM has been reduced by more than 50–60% (Souza et al., 2006(b)). 
Determination of -cell mass in T2DM patients can become relevant in the future (Rhodes et 
al., 2005).  
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4. Translation of PET imaging from animals to humans 
As mentioned before, PET has been applied to determine the PK study as a brain tissue PK 
measurement of [18F]-FK962 in the brain in monkeys and in humans. A mixture of a tracer 
amount of [18F]-FK962 and cold FK962 was administrated orally to conscious monkeys (n=3, 
doses: 0.0032 mg/kg and 0.032 mg/kg) and orally to healthy subjects (n=5, doses: 0.2 
mg/man and 2 mg/man). PET data showed a good linearity between the brain 
concentration and plasma concentration in both monkeys and humans (Fig. 8). The brain 
concentration in humans was found to be about 2-fold higher than that in monkeys at 
comparable plasma drug concentrations. In addition, the optimum dosage for oral 
administration was estimated at 2 mg in humans based on both human brain concentrations 
by PET and rat brain concentrations in a preclinical efficacy study (data not shown).  
 
(A) 
 
(B) 
 
Fig. 8. (A) Correlations between FK-962 drug concentrations in plasma and the brain in 
monkeys and humans using PET imaging. (B) Transverse PET images showing distribution 
of [18F]-FK9602 in the brain of conscious monkeys. PET images were taken 90-120 min after 
drug administration as 3.6 mm transverse slices from the lower brain (top left) to the upper 
brain (bottom right). The circle as presented in image 12 indicates the brain area in the skull. 
Thus, non-invasive imaging techniques such as PET have become available for assessment 
of drug distribution in vivo, including determination of drug brain concentrations in 
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humans. Although PET enables monitoring of regional drug concentration differences with 
a spatial resolution of a few millimetres, discrimination between bound and unbound drug 
or parent compound and metabolite is difficult. Furthermore, labeling of a PET tracer is time 
consuming and expensive and requires special expertise on radiation exposure. PET studies 
in monkeys can be useful to establish the methodology for clinical PET studies. 
Complementary use of MB study results (see session 2.2) with PET imaging can provide 
more extensive drug distribution data than MB studies alone. The use of PET imaging could 
play an important role in future drug research and development with the potential to serve 
as translational tool for clinical decision making (Brunner et al., 2006). 
5. Conclusions 
Radiolabeled compounds are commonly used in the R&D of drugs. In ADME studies 
radiosotopes are relevant to a) evaluate the exposures of the parent compound and its 
metabolites in animals and humans for validation of toxicological species, b) identify the 
major metabolic pathways in humans to support drug–drug interaction studies, c) establish 
the rate and route of excretion of a drug candidate, and d) provide metabolism data of drugs 
for regulatory filing. Using radioactive materials in ADME studies in animals and humans 
helps to identify and quantify metabolites, and reveal the major metabolite(s) and clearance 
pathways.  
In clinical development, radiolabeled compounds are used in MB studies to obtain 
information on the absorption, metabolism, and elimination of a drug. Other applications 
are the use in regional drug absorption studies to determine the PK of a drug in a novel 
modified release formulation and in microdose studies to obtain PK data after 
administration of a trace subpharmacologic quantity to human subjects. 
PET is a powerful non-invasive technique, which is used to evaluate the PK (e.g. drug 
exposure), PD (e.g. receptor binding) in animals and humans. For CNS targeted drugs, it is 
used to assess drug penetration and distribution into different areas of the brain and to 
determine the target (receptor/transporter) occupancy by the drug, which provides an 
estimation of the binding potency and durability of the drug in vivo.  In oncology PET is 
used in the diagnosis of cancer, detection of metastasis, disease staging, and for the 
prediction of patient response to treatment. In the field of diabetes mellitus, PET imaging 
could be considered a relevant tool to evaluate the effects of glucose lowering drugs on 
preservation of pancreatic ǃ-cells in diabetes patients.  
In summary, PET imaging can be used a) to estimate the pharmacological activity of a drug, 
b) to select the starting dose in first-in-man studies, c) as a surrogate biomarker for efficacy, 
and d) to proof mechanism and/or concept of a compound. This helps to determine at an 
early phase of development whether or not the drug is a good candidate to take into further 
clinical development. Thereby, PET imaging can also help to terminate the development of 
unfavourable drugs at an early stage, thereby reducing unnecessary development costs.  
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